rdf:type |
|
lifeskim:mentions |
|
pubmed:issue |
13
|
pubmed:dateCreated |
2009-12-16
|
pubmed:abstractText |
A case of gastric endocrine cell carcinoma successfully treated by FU (5-FU/UFT) +irinotecan (CPT-11) adjuvant therapy against recurrent metastases is reported with some discussion. A 69-year-old man was admitted to our hospital with severe anemia. He was diagnosed with advanced gastric cancer, T3N1H0P0M0, Stage IIIa. Total gastrectomy with pancreato-splenectomy with D2 lymph node dissection was done for curative resection. The pathological diagnosis was gastric endocrine cell carcinoma because Grimelius and Chromogranin A stained positive histologically. Seven months after operation, recurrent liver metastases with tumor embolism of the portal vein were revealed by enhanced CT examination. FU (5-FU/UFT) +CPT-11 was done as the first-line adjuvant chemotherapy. Metastatic lesion of the liver and portal vein tumor embolism was decreased. Tumor marker CA19-9 level was also decreased and within normal limits. This therapy was evaluated as a partial response (PR) in twelve months and the patient died three years and eight months after operation. Gastric endocrine cell carcinoma is known as a potentially highly malignant tumor. But in our case FU+CPT-11 controlled growth of the recurrent tumor. Based on this finding, we recommend adjuvant chemotherapy by FU+CPT-11 for gastric endocrine cell carcinoma.
|
pubmed:language |
jpn
|
pubmed:journal |
|
pubmed:citationSubset |
IM
|
pubmed:chemical |
|
pubmed:status |
MEDLINE
|
pubmed:month |
Dec
|
pubmed:issn |
0385-0684
|
pubmed:author |
pubmed-author:HaraTomohiroT,
pubmed-author:HiramatsuKiyoshiK,
pubmed-author:HosoyaJunJ,
pubmed-author:KatoKenjiK,
pubmed-author:KimuraAkiharuA,
pubmed-author:KojimaTsuyoshiT,
pubmed-author:MachikiYuichiY,
pubmed-author:OtsujiHidehikoH,
pubmed-author:SakuragawaTadayukiT,
pubmed-author:TanakaHiroshiH,
pubmed-author:TsuchiyaTomonoriT,
pubmed-author:YoshidaKatsueK
|
pubmed:issnType |
Print
|
pubmed:volume |
36
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
2641-4
|
pubmed:meshHeading |
pubmed-meshheading:20009471-Aged,
pubmed-meshheading:20009471-Antimetabolites, Antineoplastic,
pubmed-meshheading:20009471-Antineoplastic Agents, Phytogenic,
pubmed-meshheading:20009471-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:20009471-Camptothecin,
pubmed-meshheading:20009471-Chemotherapy, Adjuvant,
pubmed-meshheading:20009471-Fluorouracil,
pubmed-meshheading:20009471-Gastrectomy,
pubmed-meshheading:20009471-Humans,
pubmed-meshheading:20009471-Lymph Node Excision,
pubmed-meshheading:20009471-Male,
pubmed-meshheading:20009471-Neoplasm Metastasis,
pubmed-meshheading:20009471-Stomach Neoplasms,
pubmed-meshheading:20009471-Tegafur,
pubmed-meshheading:20009471-Uracil
|
pubmed:year |
2009
|
pubmed:articleTitle |
[A Case of gastric endocrine cell carcinoma successfully treated by FU plus irinotecan(CPT-11)adjuvant therapy against recurrent metastases].
|
pubmed:affiliation |
Dept. of Surgery, Kiryu Kosei General Hospital.
|
pubmed:publicationType |
Journal Article,
English Abstract,
Case Reports
|